Objective: The aim of this study was to identify the active anti-ischemic components of Pterocypsela elata (P. elata) using a network pharmacology approach to construct an effective component anti-cerebral ischemic target network and systematically analyze this medicinal material. Methods: Pharmacological studies have shown that P. elata has an obvious effect against cerebral ischemia. To identify the potential targets, 14 components of P. elata were docked to each structural element of the targets in the DRAR-CPI database by reverse docking technology. We then compared the identified potential targets with FDA-approved targets for stroke/cerebral infarction treatment in the DrugBank database and identified the active components of P. elata and their potential targets for stroke/cerebral infarction treatment. The active component-target networks were constructed using Cytoscape 3.5.1 software. The target protein-protein interactions were analyzed using the STRING database. KEGG pathway analysis and gene ontology (GO) enrichment analysis were performed through the Database for Annotation, Visualization and Integrated Discovery (DAVID). Results: There were 14 active components identified from P. elata and 21 potential targets identified for cerebral ischemia treatment, including carbonic anhydrase 2, ribosyldihydronicotinamide dehydrogenase, cholinesterase, and glutathione S-transferase P. The main involved pathways include metabolic pathways, complement and coagulation cascades and steroid hormone biosynthesis. Conclusion: Through a network pharmacology approach, we predicted the active components of P. elata and their potential targets for cerebral ischemia treatment. Our results provide new perspectives and clues for further studies on the anti-cerebral ischemia mechanism of P. elata.
α-Fe2O3 has high potential energy storage capacity and can serve as a green and low-cost anode material for lithium-ion batteries. However, α-Fe2O3 suffers large volume expansion and pulverization. Based on DFT calculations, TiO2 can effectively maintain the integrity of the crystal structure during the discharge/charge process. Well-defined cubic α-Fe2O3 is coated with a TiO2 layer using the hydrothermal method with the assistance of oxalic acid surface treatment, and then α-Fe2O3@TiO2 with tunable buffer chambers is obtained by altering the hydrochloric acid etching time. With the joint efforts of the buffer chamber and the robust structure of the TiO2 layer, α-Fe2O3@TiO2 alleviates the expansion of α-Fe2O3 during the discharge/charge process. The optimized sample (FT-1h) achieves good cycling performance. The reversible specific capacity remains at 893.7 mA h g-1, and the Coulombic efficiency still reaches up to 98.47% after 150 cycles at a current density of 100 mA g−1. Furthermore, the reversible specific capacity can return to 555.5 mA h g−1 at 100 mA g−1 after cycling at a high current density. Hence, the buffer chamber and the robust TiO2 layer can effectively improve the cycling stability and rate performance of α-Fe2O3.
18 December 2025 in Journal of Integrative Neuroscience
Background: Quercetin is a naturally occurring flavonoid widely distributed in plants that exhibits various biological activities, including anti-inflammatory, antioxidant, and neuroprotective effects. It exhibits a potential role in sleep regulation and homeostasis; however, its specific effects on sleep-wake cycles and underlying mechanisms remain unelucidated. Methods: To systematically investigate the regulatory role of quercetin in sleep architecture and homeostatic recovery, polysomnography (PSG) was used to monitor sleep parameters in mice under normal circadian rhythms and acute sleep deprivation (ASD). Immunofluorescence staining was performed to assess the expression of cellular proto-oncogene protein Fos (c-Fos) and microglial activation in sleep-related brain regions, including the medial prefrontal cortex (mPFC), nucleus accumbens (NAc), bed nucleus of the stria terminalis (BNST), paraventricular thalamic nucleus (PVT), hippocampal dentate gyrus (DG), basolateral amygdala (BLA), and periaqueductal gray (PAG). Results: Under normal circadian conditions, high-dose quercetin promoted non-rapid eye movement (NREM) sleep in mice. In ASD models, quercetin enhanced NREM sleep rebound during the early recovery phase. It sustained higher levels of wakefulness during the subsequent light phase, exhibiting its dual role in accelerating homeostatic recovery while balancing circadian arousal. Immunofluorescence analyses showed that quercetin markedly suppressed c-Fos expression in the mPFC, BLA, and PVT under sleep-deprived conditions. Additionally, it inhibited microglial activation in the mPFC and NAc. Conclusion: These results mechanistically associate the sleep-regulatory effects of quercetin with its dual inhibition of neuronal hyperactivity in sleep-associated brain regions and neuroinflammatory responses. Altogether, this study identifies quercetin as a novel natural modulator of sleep homeostasis, underscoring its therapeutic potential for sleep disorders via anti-excitatory and anti-inflammatory mechanisms.